Hostname: page-component-5c6d5d7d68-vt8vv Total loading time: 0.001 Render date: 2024-08-22T00:41:49.676Z Has data issue: false hasContentIssue false
  • English
  • Français

Expression of disintegrin and metalloproteinase family proteins 10, 12 and 17 in cholesteatoma

Published online by Cambridge University Press:  15 January 2013

S Erbek ,
H Erinanc ,
E Hizal  and
L N Ozluoglu
S Erbek*
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Baskent University, Ankara, Turkey
H Erinanc
Affiliation:
Department of Pathology, Faculty of Medicine, Baskent University, Ankara, Turkey
E Hizal
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Baskent University, Ankara, Turkey
L N Ozluoglu
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Baskent University, Ankara, Turkey
*
Address for correspondence: Dr Seyra Erbek, Department of Otolaryngology, Baskent University Hospital, Fevzi Çakmak Cd 10 Sk No 45, 06490 Bahçelievler, Ankara, Turkey Fax: +90 312 223 7333 E-mail: seyraerbek@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Proteases of the disintegrin and metalloproteinase family (also known as ADAM proteins) are involved in various physiological and pathological processes. This study assessed the expression of disintegrin and metalloproteinase family proteins 10, 12 and 17 in cholesteatoma.

Materials and methods:

The study evaluated cholesteatoma specimens from 19 patients, and external ear canal skin samples from 7 of the same patients (as controls), for the expression of disintegrin and metalloproteinase family proteins 10, 12 and 17, using immunohistochemical methods.

Results and analysis:

The study observed over-expression of proteins 10 and 17 in blood vessels, and over-expression of proteins 12 and 17 in cholesteatoma stroma. Immunostaining scores for proteins 10, 12 and 17 in epithelial and inflammatory cells from cholesteatoma specimens versus control specimens showed no statistically significant differences.

Conclusion:

Over-expression of disintegrin and metalloproteinase family proteins 10, 12 and 17 in cholesteatoma may be related to cholesteatoma pathogenesis. These proteins deserve further study as they may represent potential targets for cholesteatoma treatment.

Keywords

CholesteatomaADAM proteinsADAM-10 protein, humanADAM12 protein, humanADAM17 protein, human
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 2 , February 2013 , pp. 153 - 158
Copyright
Copyright © JLO (1984) Limited 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented at the 1st Turkish National Congress of Otology and Neurotology, 12–16 May 2010, Gazimagosa, Cyprus

References

1Semaan, MT, Megerian, CA. The pathophysiology of cholesteatoma. Otolaryngol Clin North Am 2006;39:1143–59CrossRefGoogle ScholarPubMed
2Schonermark, M, Mester, B, Kempf, HG, Blaser, J, Tschesche, H, Lenarz, T. Expression of matrix-metalloproteinases and their inhibitors in human cholesteatomas. Acta Otolaryngol 1996;116:451–6CrossRefGoogle ScholarPubMed
3Schmidt, M, Grunsfelder, P, Hoppe, F. Up-regulation of matrix metalloprotease-9 in middle ear cholesteatoma – correlations with growth factor expression in vivo? Eur Arch Otorhinolaryngol 2001;258:472–6CrossRefGoogle ScholarPubMed
4Schmidt, M, Grunsfelder, P, Hoppe, F. Induction of matrix metalloproteinases in keratinocytes by cholesteatoma debris and granulation tissue extracts. Eur Arch Otorhinolaryngol 2000;257:425–9CrossRefGoogle ScholarPubMed
5Duffy, MJ, McKiernan, E, O'Donovan, N, McGowan, PM. The role of ADAMs in disease pathophysiology. Clin Chim Acta 2009;403:31–6CrossRefGoogle ScholarPubMed
6Duffy, MJ, McKiernan, E, O'Donovan, N, McGowan, PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009;15:1140–4CrossRefGoogle ScholarPubMed
7Reiss, K, Ludwig, A, Saftig, P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther 2006;111:985–1006CrossRefGoogle ScholarPubMed
8Reiss, K, Saftig, P. The “a disintegrin and metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 2009;20:126–37CrossRefGoogle Scholar
9Moss, ML, Jin, SL, Milla, ME, Bickett, DM, Burkhart, W, Carter, HL et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733–6CrossRefGoogle ScholarPubMed
10Black, RA, Rauch, CT, Kozlosky, CJ, Peschon, JJ, Slack, JL, Wolfson, MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729–33CrossRefGoogle ScholarPubMed
11Sahin, U, Weskamp, G, Kelly, K, Zhou, HM, Higashiyama, S, Peschon, J et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769–79CrossRefGoogle ScholarPubMed
12Millichip, MI, Dallas, DJ, Wu, E, Dale, S, McKie, N. The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998;245:594–8CrossRefGoogle ScholarPubMed
13Roy, R, Wewer, UM, Zurakowski, D, Pories, SE, Moses, MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323–30CrossRefGoogle ScholarPubMed
14Asakura, M, Kitakaze, M, Takashima, S, Liao, Y, Ishikura, F, Yoshinaka, T et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002;8:35–40CrossRefGoogle ScholarPubMed
15Loechel, F, Fox, JW, Murphy, G, Albrechtsen, R, Wewer, UM. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000;278:511–15CrossRefGoogle ScholarPubMed
16Yan, SD, Huang, CC. The role of tumor necrosis factor-alpha in bone resorption of cholesteatoma. Am J Otolaryngol 1991;12:83–9CrossRefGoogle ScholarPubMed
17Yan, SD, Huang, CC. Tumor necrosis factor alpha in middle ear cholesteatoma and its effect on keratinocytes in vitro. Ann Otol Rhinol Laryngol 1991;100:157–61CrossRefGoogle ScholarPubMed
18Yetiser, S, Satar, B, Aydin, N. Expression of epidermal growth factor, tumor necrosis factor-alpha, and interleukin-1alpha in chronic otitis media with or without cholesteatoma. Otol Neurotol 2002;23:647–52CrossRefGoogle ScholarPubMed
19Omura, F, Makino, K, Amatsu, M, Itoh, H. The role of middle ear effusions and epidermal growth factor in cholesteatoma formation in the gerbilline temporal bone. Eur Arch Otorhinolaryngol 1995;252:428–32CrossRefGoogle ScholarPubMed
20Bujia, J, Holly, A, Schilling, V, Negri, B, Pitzke, P, Schulz, P. Aberrant expression of epidermal growth factor receptor in aural cholesteatoma. Laryngoscope 1993;103:326–9CrossRefGoogle ScholarPubMed
21Schulz, P, Bujia, J, Holly, A, Shilling, V, Kastenbauer, E. Possible autocrine growth stimulation of cholesteatoma epithelium by transforming growth factor alpha. Am J Otolaryngol 1993;14:82–7CrossRefGoogle ScholarPubMed
22Ergun, S, Zheng, X, Carlsoo, B. Expression of transforming growth factor-alpha and epidermal growth factor receptor in middle ear cholesteatoma. Am J Otol 1996;17:393–6Google ScholarPubMed
23Yoshikawa, M, Kojima, H, Wada, K, Tsukidate, T, Okada, N, Saito, H et al. Identification of specific gene expression profiles in fibroblasts derived from middle ear cholesteatoma. Arch Otolaryngol Head Neck Surg 2006;132:734–42CrossRefGoogle ScholarPubMed
24Macias, MP, Gerkin, RD, Macias, JD. Increased amphiregulin expression as a biomarker of cholesteatoma activity. Laryngoscope 2010;120:2258–63CrossRefGoogle ScholarPubMed
25Sudhoff, H, Bujia, J, Borkowshi, G, Koc, C, Holly, A, Hildmann, H et al. Basement membrane in middle ear cholesteatoma. Immunohistochemical and ultrastructural observations. Ann Otol Rhinol Laryngol 1996;105:804–10Google ScholarPubMed
26Ergun, S, Zheng, X, Carlsoo, B. Antigen expression of epithelial markers, collagen IV and Ki67 in middle ear cholesteatoma. An immunohistochemical study. Acta Otolaryngol 1994;114:295–302CrossRefGoogle ScholarPubMed
27Schilling, V, Holly, A, Bujia, J, Schulz, P, Kastenbauer, E. High levels of fibronectin in the stroma of aural cholesteatoma. Am J Otolaryngol 1995;16:232–5CrossRefGoogle ScholarPubMed
28Peschon, JJ, Slack, JL, Reddy, P, Stocking, KL, Sunnarborg, SW, Lee, DC et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281–4CrossRefGoogle ScholarPubMed
29Kawaguchi, M, Mitsuhashi, Y, Kondo, S. Localization of tumour necrosis factor-alpha converting enzyme in normal human skin. Clin Exp Dermatol 2004;29:185–7CrossRefGoogle ScholarPubMed
30Kawaguchi, M, Mitsuhashi, Y, Kondo, S. Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br J Dermatol 2005;152:915–19CrossRefGoogle ScholarPubMed
31Oh, ST, Schramme, A, Stark, A, Tilgen, W, Gutwein, P, Reichrath, J. Overexpression of ADAM 10 and ADAM 12 in lesional psoriatic skin. Br J Dermatol 2008;158:1371–3CrossRefGoogle ScholarPubMed
32Oh, ST, Schramme, A, Stark, A, Tilgen, W, Gutwein, P, Reichrath, J. The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas. J Cutan Pathol 2009;36:395–401CrossRefGoogle ScholarPubMed
33Duffy, MJ, Lynn, DJ, Lloyd, AT, O'Shea, CM. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb Haemost 2003;89:622–31Google ScholarPubMed
34Thabet, MM, Huizinga, TW. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 2006;7:1014–19Google ScholarPubMed